State Street(R) SPDR(R) S&P(R) Biotech ETFXBI
Type
ETF
Peer group
US equity: Healthcare
Net assets
$7.4B
Expense ratio
0.35%
1-year return
+81.6%
3 years, a year
+27.3%
5 years, a year
+4.2%
12-month yield
0.35%
Holdings
158
What it aims to do.
The State Street SPDR S&P Biotech ETF (the Fund) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| State Street Global Advisors | 8.01% |
| Apellis Pharmaceuticals Inc | 1.84% |
| JOBY Alkermes PLC | 1.45% |
| MDGL Madrigal Pharmaceuticals Inc | 1.38% |
| TGTX TG Therapeutics Inc | 1.35% |
| INSM Insmed Inc | 1.34% |
| SRRK Scholar Rock Holding Corp | 1.30% |
| Apogee Therapeutics Inc | 1.28% |
| PTGX Protagonist Therapeutics Inc | 1.24% |
| SMMT Summit Therapeutics Inc | 1.24% |
More on XBI.
- XBI overview
- XBI holdings
- XBI risk
- XBI costs
- XBI money in and out
- XBI share classes
- Compare XBI with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.